Apheresis Remains One of the Most Critical Medical Technology with Primary Application in the Collection of Donor Blood Components

     

Apheresis

Apheresis is an advanced medical technology whereby the arterial blood of an individual is passed via an artificial device into a bag and then back again. It's so-called because it doesn't involve the use of needles or any type of instrument that could possibly be contaminated with bodily fluids. Essentially, it's a non-invasive procedure where a technician inserts a cannula - or typically a narrow tube - into a patient's arterial blood vessel so that the arterial blood is extracted. Once this is accomplished, the tube is sealed back up so that it can be withdrawn, and the cannula is subsequently removed and discarded. It's then an extracorporeal therapy.

A common variation among single donor Apheresis methods is the use of immuno-suppression drugs. Apheresis doesn't require the administration of any medications, and patients are unaware that they're being administered immuno-suppressants during the procedure. Therefore, it's impossible to know whether or not the patients taking such drugs are at risk of developing allergic reactions to any ingredients contained within the blood product. In addition, immuno-suppressant drugs can alter the composition of blood products dramatically, rendering them ineffective after any period of time.

Apheresis can also use sophisticated techniques, including the delivery of platelets directly into the heart. This method of Apheresis requires that an anesthetic be injected into the patient, as well as the administration of a large amount of sodium thioglycolate. Platelets, which are rich in glucose, are the major component of the blood plasma. Once they reach the heart, platelets start producing glycolysis (breaking down sugars and starches). This assists in the production of new cells in the heart and liver, as well as cleansing the vessels. Recently, in April 2020, the U.S. Food and Drug Administration (FDA) announced Emergency Use Authorization (EUA) approval for Teurmo BCT Inc. and Marker Therapeutics AG’s D2000 Adsorption Cartridge to treat patients 18 years of age or older with confirmed Coronavirus Disease 2019 (COVID-19)

 


Comments

Post a Comment

Popular posts from this blog

Increasing Consumption and Production of Fertilizers to Upsurge the Growth of the Agrochemicals Market

Image
  Agrochemical products are those chemicals that are used to increase the production of an agricultural environment. Agrochemical chemicals typically include pesticides, fertilizers, lime precursors, acidizing and alkalizing agents (all of which are designed to alter the normal pH level of the soil), lime stabilizers, and other nutrients that are required for plant growth. These chemicals are widely used by farmers and are crucial to the functioning of modern agriculture. The use of these chemicals presents a number of concerns both from the perspective of the environment and the human body. The increasing need for improving crop production due to the growing concern of food security and lack of arable land is fueling the growth of agrochemicals market . Growing advancement in technology is raising adoption of advanced and sustainable farming practices which is again propelling the growth of the market. The increasing population coupled with the growing usage of fertilizers around th
Read more

High Prevalence of Cancer and R&D in Anti-Cd39 Antibodies to Augment Growth of Anti-body Coupled T Receptor Therapy Market

Image
  Antibody-Coupled T cell Receptor (ACTR) is an autologous engineered T cell therapy that combines the Fc receptor, CD16, with endogenous T cell signaling and costimulatory domains. It is combined with tumor-targeting antibodies to exert potent anti-tumor immune responses and eliminate cancerous cells. ACRT has demonstrated potential in the treatment of multiple myeloma and HER2+ advanced cancers. Market Dynamics R&D in anti-CD39 antibodies is expected to propel growth of the Anti-body Coupled T Receptor Therapy Market . For instance, in December 2020, Arcus Biosciences, Inc. expanded its existing partnership with WuXi Biologics, a developer of biologics technology platforms, for R&D in anti-CD39 antibodies using WuXi Bio’s proprietary technology. Moreover, high prevalence of cancer is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 canc
Read more

Increasing Prevalence of Muscular Dystrophy to Augment the Muscular Dystrophy Treatment Market Growth

Image
  Muscular dystrophy is a common disease that causes muscles to become weaker and unable to continue to develop properly. Because it often affects young children as well as adults, it can be difficult to detect. However, once symptoms are noticed, steps must be taken to prevent the disease. There are many treatment options available for muscular dystrophy. The severity of the disease will determine what type of treatment is best for your situation. Muscular dystrophy treatment involves breathing aids, therapy, surgery, or medication, which may help maintain function, but life span is often shortened. Market Dynamics: Increasing prevalence or incidence of muscular dystrophy, especially in the North America, is expected to propel the growth of the muscular dystrophy treatment market . For instance, one in 3,500 male babies born worldwide are affected with Duchenne muscular dystrophy (DMD), according to the National Organization for Rare Disorders. Moreover, in 2019, around 349 new ca
Read more